Review
Copyright ©The Author(s) 2015.
World J Gastroenterol. Jul 21, 2015; 21(27): 8271-8283
Published online Jul 21, 2015. doi: 10.3748/wjg.v21.i27.8271
Table 4 Pancreatic cancer studies n (%)
AuthorType of microsphereType of mets (patients)Response criteriaResponseMedian OS
(publish date and study type)(average dosage or activity)@ 1st assessment
Michl et al[43]SIR-SpheresPancreatic (19)RECIST9/13 (64.3) PR9 mo
(12/2013, RS)(1.0-2.5 Gbq)@ 2.6 mo (median)4/13 (35.7) PD
6 lost
Cao et al[32]SIR-SpheresPancreatic (7)RECIST2 (40) PRNo median OS
(11/2010, RS)(no dosage info)@ 1-2 mo1 (20) SD1 patient survived to 15 mo
2 (40) PD
2 lost
Pöpperl et al[45]SIR-SpheresPancreatic (1, data extracted from larger study)PET1 (100) RegressionNone
(4/2005, PC)(mean 2.27 Gbq)@ 3 mo